Carestream Molecular Imaging, a division of Carestream Health, Inc., announced at the Joint Molecular Imaging Conference the introduction of KODAK X-SIGHT, new large stokes shift dyes for fluorescent in vivo imaging applications, which are reactive dyes designed to enable researchers and scientists to maximize the fluorescent signal while minimizing auto-fluorescence issues during in vivo imaging.

“Stokes shift” refers to the separation of absorption and emission maxima. Having a significantly larger Stokes shift—greater than 80 nanometers in the case of KODAK X-SIGHT Dyes—helps researchers eliminate much of the background that typically obstructs the fluorescent signal while allowing researchers to excite and emit the dyes at their maxima, thus resulting in far greater signal to noise. Most commercially available dyes typically have a Stokes shift between 20-30 nanometers.

In an organism, the KODAK X-SIGHT Dyes can illuminate a region of interest when excited by the appropriate wavelength of fluorescent light, thus allowing the researcher to visualize their target. While the KODAK X-SIGHT Imaging Agents have been optimized for KODAK Image Station and In-Vivo Systems, they are also compatible with other commercially available digital imaging systems.

“Our new KODAK X-SIGHT Large Stokes Shift Dyes, characterized by near infrared emission and a large Stokes shift, enable researchers to achieve a higher sensitivity of fluorescent detection deeper into tissue,” said Shahram Hejazi, PhD, President of Carestream Molecular Imaging. “With superior performance when compared to other commercially available products, these new dyes validate our outstanding dye chemistry expertise and leadership in fluorescent imaging.”
KODAK X-SIGHT Dyes will be available this fall for preclinical use.


Related Content

News | Radiology Business

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Breast Imaging

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
News | Interventional Radiology

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time November 03, 2023
arrow
Subscribe Now